Long term impact of the low FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability and healthcare utilisation in irritable bowel syndrome by O'Keeffe, M. et al.
Neurogastroenterology & Motility. 2017;e13154.	 wileyonlinelibrary.com/journal/nmo	 	 | 	1 of 13
https://doi.org/10.1111/nmo.13154
© 2017 John Wiley & Sons Ltd
Received:	9	March	2017  |  Accepted:	9	June	2017
DOI: 10.1111/nmo.13154
O R I G I N A L  A R T I C L E
Long- term impact of the low- FODMAP diet on gastrointestinal 
symptoms, dietary intake, patient acceptability, and healthcare 
utilization in irritable bowel syndrome
M. O’Keeffe1 | C. Jansen1 | L. Martin1 | M. Williams2 | L. Seamark2 |  
H. M. Staudacher1 | P. M. Irving1,3 | K. Whelan1,3 | M. C. Lomer1,3
Abbreviations:	DRV,	dietary	reference	value;	FODMAP(s),	fermentable	oligosaccharides,	disaccharides,	monosaccharides,	and	polyols;	IBS,	irritable	bowel	syndrome;	NICE,	National	Institute	for	
Health	and	Care	Excellence;	QOL,	quality	of	life;	RCT,	randomized	controlled	trial;	SD,	standard	deviation.
1Faculty	of	Life	Sciences	and	Medicine,	
Diabetes	and	Nutritional	Sciences	Division,	
King’s	College	London,	London,	UK
2Community	Dietetics	Service,	Somerset	
Partnership	NHS	Foundation	Trust,	
Bridgwater,	Somerset,	UK
3Department of Gastroenterology, Guy’s and 
St	Thomas’	NHS	Foundation	Trust,	London,	
UK
Correspondence
Miranda	Lomer,	Diabetes	and	Nutritional	
Sciences	Division,	King’s	College	London,	
London,	UK.
Email:	miranda.lomer@kcl.ac.uk
Abstract
Background: The	low-	FODMAP	diet	is	a	frequently	used	treatment	for	irritable	bowel	
syndrome	(IBS).	Most	research	has	focused	on	short-	term	FODMAP	restriction;	how-
ever,	guidelines	recommend	that	high-	FODMAP	foods	are	reintroduced	to	individual	
tolerance.	This	study	aimed	to	assess	the	long-	term	effectiveness	of	the	low-	FODMAP	
diet	following	FODMAP	reintroduction	in	IBS	patients.
Methods: Patients	with	IBS	were	prospectively	recruited	to	a	questionnaire	study	fol-
lowing	completion	of	dietitian-	led	low-	FODMAP	education.	At	baseline	and	following	
FODMAP	restriction	(short	term)	only,	gastrointestinal	symptoms	were	measured	as	
part	of	routine	clinical	care.	Following	FODMAP	reintroduction,	(long	term),	symptoms,	
dietary	intake,	acceptability,	food-	related	quality	of	life	(QOL),	and	healthcare	utiliza-
tion	 were	 assessed.	 Data	 were	 reported	 for	 patients	 who	 continued	 long-	term	
FODMAP	restriction	(adapted	FODMAP)	and/or	returned	to	a	habitual	diet	(habitual).
Key Results: Of 103 patients, satisfactory relief of symptoms was reported in 12% at 
baseline,	61%	at	short-	term	follow-	up,	and	57%	at	long-	term	follow-	up.	At	long-	term	
follow-	up,	84	 (82%)	patients	continued	an	 ‘adapted	FODMAP’	diet	 (total	FODMAP	
intake	mean	20.6,	SD	14.9	g/d)	compared	with	19	(18%)	of	patients	following	a	‘ha-
bitual’	diet	(29.4,	SD	22.9	g/d,	P=.039).	Nutritional	adequacy	was	not	compromised	for	
either	group.	The	‘adapted	FODMAP’	group	reported	the	diet	cost	significantly	more	
than	the	‘habitual’	group	(P<.001)	and	affected	social	eating	(P<.01)	but	there	was	no	
effect	on	food-	related	QOL.	Healthcare	utilization	was	similar	between	both	groups.
Conclusion and Inferences: Low-	FODMAP	education	is	effective	for	long-	term	IBS	man-
agement,	enables	a	nutritionally	adequate	diet,	and	is	broadly	acceptable	to	patients.
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1  | INTRODUCTION
Irritable	bowel	syndrome	(IBS)	is	the	most	commonly	diagnosed	gas-
trointestinal disorder1	 and	 is	 characterized	 by	 episodic	 abdominal	
pain and altered defecation.2	This	heterogeneous	disorder	is	a	leading	
cause of morbidity among the general population and global preva-
lence is estimated at 11% with women more commonly affected than 
men.3	It	has	a	significant	impact	on	patients’	health-	related	quality	of	
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life	 (QOL)4,5	 and	 is	 associated	with	 increased	healthcare	utilization6 
and	has	significant	economic	consequences.1,7	Over	80%	of	 IBS	pa-
tients	report	food-	related	symptoms	and	this	is	independently	associ-
ated	with	reduced	QOL.8
Dietary restriction of fermentable oligosaccharide, disaccharide, 
monosaccharide,	and	polyols	(low-	FODMAP	diet)	is	an	effective	treat-
ment	for	IBS	symptoms,	with	50-	76%	of	patients	demonstrating	a	clini-
cal response.9-15	Randomized10,13,16,17	and	non-	randomized	trials14,15,18 
demonstrate	short-	term	(up	to	6	weeks)	global	and	individual	symptom	
improvement	 in	 IBS	 and	 have	 been	 reviewed	 elsewhere.19	 The	 diet	
involves	 restriction	of	high-	FODMAP	foods	 for	4-	6	weeks	to	achieve	
symptom improvement followed by systematic reintroduction to iden-
tify	 the	 tolerance	 threshold	 for	 individual	 FODMAPs,	which	 enables	
long-	term	self-	management	of	symptoms	and	increasing	dietary	variety.
The	 low-	FODMAP	diet	 is	a	complex	 intervention	and	should	be	
implemented with counseling from a dietitian.20-22	To	date,	 research	
has	 reported	 on	 clinical	 and	 nutritional	 outcomes	 following	 short-	
term	FODMAP	restriction.10,13 However, there are concerns regarding 
the	 nutritional	 adequacy	 of	 the	 diet	 and	 inadequate	 calcium	 intake	
following	4	weeks	of	FODMAP	restriction.13 Furthermore, there are 
concerns	 regarding	 long-	term	 acceptability	 of	 the	 diet.12,18 Data on 
the	 long-	term	 effectiveness,	 nutritional	 adequacy	 and	 acceptability	
of	 the	 low-	FODMAP	diet	 are	 scarce.	 For	 example,	 studies	 have	 re-
ported symptoms retrospectively12,23 or symptoms and acceptability 
prospectively.18,24 However, there has been no evaluation of dietary 
intake	or	other	aspects	of	the	diet	in	relation	to	food-	related	QOL	and	
effects	on	healthcare	utilization	in	the	long	term.
The	extensive	elimination	of	 foods	and	the	 likelihood	that	many	
patients	 that	 respond	 will	 require	 dietary	 modification	 in	 the	 long	
term,	coupled	with	the	increasing	use	of	the	low-	FODMAP	diet	war-
rants	a	comprehensive	evaluation	of	long-	term	outcomes.	Therefore,	
the	aims	of	this	study	were	to	assess	the	long-	term	impact	of	the	low-	
FODMAP	diet	on	clinical	response,	high-	and	low-	FODMAP	food	fre-
quency,	nutritional	adequacy,	dietary	acceptability,	food-	related	QOL,	
and	healthcare	utilization	in	patients	with	IBS.
2  | MATERIALS AND METHODS
2.1 | Study design
This	study	was	a	prospective	long-	term	follow-	up	postal	questionnaire	
study.	Consecutive	patients	diagnosed	with	IBS	in	accordance	with	the	
National	 Institute	 of	 Health	 and	 Care	 Excellence	 (NICE)	 (abdominal	
pain/discomfort, bloating or change in bowel habit for at least 6 months 
in	the	absence	of	organic	disease)21 were recruited from both second-
ary	care	(Guy’s	and	St	Thomas’	NHS	Foundation	Trust,	London,	UK)	and	
primary	care	(Somerset	Partnership	NHS	Foundation	Trust,	Somerset,	
UK).	 All	 eligible	 patients	 had	 been	 counseled	 on	 the	 low-	FODMAP	
diet by a specialist gastroenterology dietitian and had received two 
clinical appointments; the initial appointment for dietary education on 
FODMAP	restriction	(baseline)	and	the	follow-	up	appointment	at	least	
6	weeks	 later	when	 they	 had	been	 following	 the	 low-	FODMAP	diet	
(short-	term	follow-	up)	at	which	point	they	were	educated	on	FODMAP	
reintroduction.	The	prospective	long-	term	follow-	up	performed	as	part	
of	this	study	(long-	term	follow-	up)	occurred	at	least	6	months	and	no	
more	than	18	months	after	short-	term	follow-	up.	Thus,	data	were	col-
lected from three time points, the first two of which were part of rou-
tine clinical care where only symptom data were collected.
At	baseline,	patients	had	been	instructed	to	restrict	their	intake	of	
high-	FODMAP	foods	for	at	least	6	weeks.	Written	guidance	on	suitable	
and	unsuitable	foods	and	appropriate	low-	FODMAP	food	products	for	
the	restriction	phase	of	the	diet	was	provided.	At	short-	term	follow-	up,	
counseling	on	FODMAP	 reintroduction	was	provided.	Patients	were	
instructed	 to	 undertake	 3-	day	 FODMAP	 food	 challenges	 using	 in-
creasing	food	portions	to	identify	individual	FODMAPs	that	triggered	
symptoms.	This	 process	 enabled	patients	 to	 reintroduce	 some	high-	
FODMAP	foods	to	their	tolerance	threshold.	Both	appointments	were	
conducted as per normal clinical practice as described elsewhere.14,15
Patients	were	 ineligible	 for	 the	 prospective	 long-	term	 follow-	up	
study	 if	 they	 had	 failed	 to	 attend	 the	 short-	term	 follow-	up	 clinical	
appointment;	 had	 experienced	 an	 acute	 gastrointestinal	 episode	 in	
the	4	weeks	prior	 to	 long-	term	follow-	up;	had	been	diagnosed	with	
a	co-	existing	gastrointestinal	disease	(eg,	inflammatory	bowel	disease,	
celiac	disease),	an	eating	disorder	or	a	significant	psychiatric	disorder	
since baseline; or were unable to give informed consent.
The	study	was	carried	out	in	accordance	with	the	Declaration	of	
Helsinki	and	was	approved	by	the	East	of	Scotland	Research	and	Ethics	
Committee	(REC	reference:	13/ES/0158).	Participation	was	voluntary	
and	all	data	were	confidential	and	were	reported	anonymously.	All	pa-
tients	provided	written	informed	consent	at	long-	term	follow-	up.
At	the	prospective	long-	term	follow-	up	patients	were	asked	to	report	
their current weight and height and whether their weight had changed 
during	FODMAP	restriction.	Patients	were	also	asked	to	rate	their	cur-
rent	knowledge	of	the	 low-	FODMAP	diet	using	a	5-	point	Likert	scale	
(extremely	poor;	below	average;	average;	above	average;	excellent).
2.2 | Gastrointestinal symptoms and stool output
Data for symptoms and stool output were available for baseline, 
short-	term	follow-	up	(from	clinical	records),	and	long-	term	follow-	up	
Key Points
•	 The	low-FODMAP	diet	is	a	successful	treatment	for	irri-
table	bowel	syndrome	(IBS).	However,	 there	are	 limited	
data	 on	 the	 long-term	 effects	 of	 the	 diet.	 The	 current	
study	 assessed	 the	 long-term	 impact	 of	 the	 low-FOD-
MAP	diet	on	clinical	response,	dietary	intake,	patient	ac-
ceptability,	food-related	QOL,	and	healthcare	use.
•	 Over	 half	 of	 patients	 report	 long-term	 symptom	 relief,	
the	 diet	 is	 nutritionally	 adequate	 and	 acceptable	 to	
patients.
•	 The	 findings	 support	 using	 the	 low-FODMAP	 diet	 for	
long-term	IBS	management.
     |  3 of 13O’KEEFFE Et al.
(from	prospective	survey).	Data	from	baseline	and	short-	term	follow-
	up	 clinical	 appointments	were	matched	 to	 the	 long-	term	 follow-	up	
data	using	a	unique	anonymized	identifier.
Global	 symptom	 response	 used	 the	 question	 “Do you currently 
have satisfactory relief of your gut symptoms?”.25	The	Gastrointestinal	
Symptom	Rating	Scale	(GSRS)	was	used	to	assess	the	severity	(absent,	
mild,	moderate,	severe)	of	abdominal	pain,	bloating,	flatulence,	burp-
ing, borborygmi, urgency, incomplete evacuation, nausea, heartburn, 
acid regurgitation, and lethargy.26	Data	on	stool	frequency	and	con-
sistency	(Bristol	stool	form	scale)	were	collected	at	all	time	points	and	
based on an average for the last 7 days.27	IBS	subtype	was	based	on	
retrospective reporting of predominant stool consistency: those re-
porting	Bristol	Stool	Form	type	1	or	2	were	classified	as	constipation-	
predominant	IBS	(IBS-	C),	those	reporting	Bristol	Stool	Form	type	6	or	
7	were	classified	as	diarrhea-	predominant	IBS	(IBS-	D),	those	reporting	
Bristol	Stool	Form	type	1	or	2	and	6	or	7	were	classified	as	mixed	sub-
type	IBS	(IBS-	M),	and	those	reporting	Bristol	Stool	Form	type	3,	4,	or	
5	were	classified	as	IBS	unclassified	(IBS-	U).
2.3 | Dietary intake, acceptability, and food- related 
quality of life
Dietary	 intake	 was	 assessed	 at	 long-	term	 follow-	up	 using	 the	
Comprehensive	 Nutrition	 Assessment	 Questionnaire	 (CNAQ)	 which	
is	a	semi-	quantitative	food	frequency	questionnaire	validated	to	assess	
FODMAP	and	nutrient	intake.28	FODMAP	intake	was	determined	using	
an	automated	entry	 system	available	online	 (http://www.cnaq.com.au).	
Nutritional	 adequacy	 was	 assessed	 by	 comparison	 of	 nutrient	 intakes	
against	the	United	Kingdom	dietary	reference	values.29-31	Frequency	data	
on	the	consumption	of	foods	high	and	low	in	individual	FODMAPs	was	as-
sessed based on cutoffs.32	Each	food	frequency	questionnaire	food	item	
was	categorized	as	high-	or	low-	FODMAP	and,	if	high,	which	FODMAP(s)	
they	contained.	Food	items	were	also	categorized	into	food	groups	and	
sub-	groups	to	assess	daily	intakes.	Low-	FODMAP	speciality	foods	were	
included	within	 their	 respective	 food	 group,	 eg,	 low-	FODMAP	 cereals	
and	grains	 included	gluten-	free	bread,	and	low-	FODMAP	milk	 included	
lactose-	free	cow’s	milk.	Additionally,	daily	intakes	of	onion	and	garlic	were	
assessed as they contribute a large amount of fructans to the diet.33
The	proportion	of	patients	who	consumed	foods	high	 in	 individ-
ual	 FODMAPs	 (fructans,	 galacto-	oligosaccharides,	 lactose,	 fructose,	
sorbitol,	 and	mannitol)	 at	 least	once	 a	week	was	 assessed	between	
groups.
Patients	were	asked	to	record	their	dietary	adherence	to	long-	term	
FODMAP	restriction	using	a	4-	point	Likert	scale:	‘continued	strict	low-	
FODMAP	diet’,	‘reintroduced	high-	FODMAP	foods	to	tolerance’,	‘con-
tinued	low-	FODMAP	diet	50%	of	the	time’,	‘returned	to	habitual	diet’.	
The	‘adapted	FODMAP’	group	included	the	first	three	of	these.
Acceptability	 of	 dietary	 restriction	 was	 assessed	 at	 long-	term	
follow-	up	using	a	14-	item	questionnaire	adapted	from	the	nutrition-	
related	QOL	 questionnaire.34	 Questions	 considered	 the	 impact	 and	
challenges of diet on eating environment, travel, meal enjoyment, cost, 
shopping,	and	cooking.	Data	were	scored	using	a	5-	point	Likert	scale	
(strongly	agree,	agree,	neutral,	disagree,	and	strongly	disagree).
The	 impact	 of	 the	 low-	FODMAP	 diet	 on	QOL	was	 assessed	 at	
long-	term	follow-	up	using	a	seven-	item	questionnaire	based	on	a	ge-
neric	validated	food-	related	QOL	tool	(Satisfaction	with	Food-	related	
Life).35	Data	were	scored	using	a	5-	point	Likert	scale	(strongly	agree,	
agree,	neutral,	disagree,	and	strongly	disagree).
2.4 | Healthcare utilization and work absenteeism
At	long-	term	follow-	up	patients	were	asked	to	record	how	often	they	
visited their general practitioner or gastroenterologist for gastrointes-
tinal	symptoms	during	the	previous	12	months,	what	IBS	medication	
they	were	currently	taking,	 if	 it	had	changed	since	being	advised	on	
the	low-	FODMAP	diet,	and	whether	they	were	absent	from	work	due	
to their gastrointestinal symptoms in the same period.
2.5 | Statistical analysis
The	primary	outcome	was	global	symptom	relief	at	long-	term	follow-
	up	compared	with	baseline.	The	sample	size	was	calculated	to	detect	
a difference in the primary outcome assuming 60% of patients who 
had	 reported	 global	 symptom	 relief	 at	 short-	term	 follow-	up	 would	
continue	to	report	it	at	long-	term	follow-	up	vs	10%	of	patients	who	
had	not	reported	global	symptom	relief	at	short-	term	follow-	up	would	
report	 it	 at	 long-	term	 follow-	up.	A	 total	of	80	completed	question-
naires	were	required	at	90%	power	for	detecting	a	difference	in	the	
primary outcome at P=.05	 significance	 level.	 From	previous	 experi-
ence	of	postal	invitation	to	a	dietary	intake	study,	it	was	anticipated	
that at least 20% of subjects invited would complete and return the 
questionnaires,36	thus	it	was	assumed	that	380	patients	would	be	in-
vited	to	achieve	the	sample	size	requirement.
Returned	 questionnaires	 were	 excluded	 from	 analysis	 if	 more	
than	10%	of	questions	had	not	been	answered.	Individual	symptom	
responses	assessed	by	the	GSRS	were	collapsed	into	a	dichotomous	
response	to	report	the	presence	or	absence	of	‘moderate	or	severe’	
symptoms as previously reported.15	Stool	frequency	was	reclassified	
into	 normal	 (once	 every	 3	days	 to	 three	 times	 a	 day)	 or	 abnormal	
(less	than	once	every	3	days	or	more	than	three	times	a	day).	Stool	
consistency	was	 reclassified	 into	 normal	 (Bristol	 Stool	 Form	 types	
3,	 4,	 or	 5)	 or	 abnormal	 (Bristol	 Stool	 Form	 types	 1,	 2,	 6,	 or	 7)	 as	
previously reported.15	For	dietary	intake,	dietary	acceptability,	food-	
related	 QOL,	 work	 absenteeism,	 and	 healthcare	 utilization	 com-
parisons, patients were collapsed into a dichotomous response set 
according	to	whether	they	returned	to	a	habitual	diet	(‘habitual’)	or	
continued	 to	 restrict	high-	FODMAP	 foods	 (‘adapted	FODMAP’)	 at	
long-	term	 follow-	up.	Categorical	data	 for	dietary	acceptability	 and	
food-	related	QOL	were	collapsed	into	three	group	response	sets	to	
provide clinically meaningful interpretation and data distribution for 
analysis.
All	data	were	analyzed	using	SPSS,	version	22	(SPSS	Inc,	Chicago,	
IL,	USA).	Demographic	and	baseline	symptoms	were	analyzed	descrip-
tively.	Data	are	reported	as	mean±standard	deviation	(SD)	with	95%	
confidence	intervals	for	continuous	data	and	n	(%)	for	categorical	data,	
unless	otherwise	 indicated.	A	Bonferroni	 correction	was	 applied	 for	
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multiple	comparisons	where	required.	Statistical	significance	was	con-
sidered where P<.05.
Macronutrient	and	micronutrient	 intakes	were	assessed	for	ade-
quacy	in	comparison	to	the	UK	recommendations.	Food	frequency	in-
takes	from	the	food	frequency	questionnaire	were	converted	to	daily	
intakes	using	previously	published	conversion	factors.37	Daily	intakes	
were adjusted to account for the total number of foods reported as 
consumed by each subject.
3  | RESULTS
A	 total	 of	 375	 (n=309	 secondary	 care,	 n=66	primary	 care)	 patients	
were eligible and invited to participate in the study. Of these, 232 did 
not respond to the invitation to participate, thus 143 were consented 
and	 recruited	 (Figure	1).	 Thirty	 patients	 agreed	 to	 take	part	 initially	
but	did	not	return	the	questionnaire	while	seven	withdrew	stating	lack	
of time or personal reasons, and three patients returned incomplete 
questionnaire	 and	were	excluded	 from	analysis.	Therefore,	103	pa-
tients	were	analyzed	at	 long-	term	 follow-	up	 (Table	1)	with	74	 from	
secondary	care	and	29	from	primary	care.	All	baseline	demographics	
were	similar	between	groups	except	for	gender	and	age.	There	were	
significantly	fewer	males	from	primary	care	(females	from	secondary	
care 50 [49%], females from primary care 26 [25%], males from sec-
ondary care 24 [23%], males from primary care 3 [3%]; P=.022)	and	
the patients recruited from secondary care were significantly younger 
than	 the	 patients	 recruited	 from	 primary	 care	 (secondary	 care	
45.3±15 year vs primary care 56.6±12 year; P<.001).	At	baseline,	20	
patients	had	IBS-	C,	39	patients	had	IBS-	D,	21	patients	had	IBS-	M,	and	
23	patients	had	IBS-	U.
3.1 | Gastrointestinal symptoms and stool output
At	 baseline,	 12	 (12%)	 patients	 reported	 satisfactory	 symptom	 re-
lief,	which	 increased	 to	63	 (61%)	 patients	 at	 short-	term	 follow-	up	
(FODMAP	restriction)	and	to	59	(57%)	patients	at	long-	term	follow-
	up	(Figure	2;	P=.003).	There	were	no	significant	differences	for	sat-
isfactory	relief	between	settings	at	baseline	(secondary	care	8	[8%]	
vs primary care 4 [4%]; P=.671),	short-	term	follow-	up	relief	(second-
ary care 42 [41] vs primary care 21 [20%]; P=.143),	and	 long-	term	
follow-	up	relief	(secondary	care	41	[40%]	vs	primary	care	18	[18%];	
P=.539).	 Of	 the	 63	 patients	 with	 satisfactory	 relief	 at	 short-	term	
follow-	up,	44	(70%)	maintained	this	in	the	long	term.	The	proportion	
of patients reporting presence of individual symptoms significantly 
decreased	over	 time	 (Figure	3).	 Specifically,	 abdominal	 pain,	 bloat-
ing, and flatulence were reported in over 60% of patients at baseline 
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and	decreased	by	at	least	a	third	at	long-	term	follow-	up.	There	was	
a significant reduction in the proportion of patients reporting abnor-
mal	stool	frequency	(baseline	21%;	short-	term	follow-	up	7%;	 long-	
term	follow-	up	7%	P<.001)	and	abnormal	stool	consistency	(baseline	
65%;	short-	term	follow-	up	43%;	 long-	term	follow-	up	42%	P=.001)	
(Cochran	test).
3.2 | Dietary intake, acceptability, and food- related 
quality of life
At	 long-	term	 follow-	up,	 84	 (82%)	 patients	 continued	 to	 follow	 an	
‘adapted	FODMAP’	diet,	while	19	(18%)	returned	to	a	‘habitual’	diet.	
There	were	no	 significant	differences	between	groups	at	 long-	term	
follow-	up	 for	 energy	 and	 nutrient	 intakes,	 except	 for	 folate	 and	
vitamin	A	which	were	both	higher	 in	 the	 ‘adapted	FODMAP’	group	
compared	with	the	‘habitual’	group	(Table	2).	At	least	95%	of	patients	
met the appropriate dietary reference value for energy and the ma-
jority	of	nutrients	in	both	groups.	Total	carbohydrate	and	calcium	in-
takes,	which	have	previously	been	reported	as	lower	than	controls	in	
short-	term	low-	FODMAP	diet	studies,9,13 were not different between 
the	 ‘adapted	 FODMAP’	 group	 compared	 with	 the	 ‘habitual’	 group	
(total	carbohydrate:	250±94.4	g/d	vs	252±95.5	g/d,	P=.925; calcium: 
960±608	mg/d	vs	1168±695	mg/d,	P=.230,	respectively).
Total	 FODMAP	 intake	 was	 significantly	 lower	 for	 the	 ‘adapted	
FODMAP’	group	(20.6±14.9	g/d)	compared	with	the	‘habitual’	group	
(29.4±22.9	g/d,	P=.039;	Table	2).	No	significant	differences	were	noted	
between	 the	groups	 for	 individual	 FODMAP	 intakes	 although	 there	
was	a	trend	for	lower	lactose	intake	in	the	‘adapted	FODMAP’	group	
Demographic
Long- term 
follow- up (n=103)
Secondary 
care (n=74)
Primary 
care (n=29) P
Gender
Female	n	(%) 76	(74) 50	(49) 26	(25) .022b
Male	n	(%) 27	(26) 24	(23) 3	(3)
Age	(years)	mean±SD 49±15 45.3±15 56.6±12 <.001c
Weight	(kg)	mean±SD 69.7±13.7 70.5±13.7 68.0±13.9 0.410c
BMI	(kg/mb)	mean±SD 24.8±3.9 24.5±3.6 25.2±4.3 0.404c
Weight	change	since	low-	FODMAP	education
Lost	weight	n	(%) 42	(41) 31	(30) 11	(11) 0.064b
Remained	the	same	weight	n	(%) 48	(47) 30	(29) 18	(18)
Gained	weight	n	(%) 13	(12) 13	(12) 0
Knowledge	and	understanding	of	the	low-	FODMAP	diet	n	(%)a
Average	n	(%) 35	(35) 28	(27) 7	(7) 0.465b
Above	average	n	(%) 55	(56) 38	(37) 17	(17)
Excellent	n	(%) 9	(9) 5	(5) 4	(4)
aMissing n=4.
bChi-	squared	between	settings.
cIndependent t test between settings.
TABLE  1 Demographics of irritable 
bowel	syndrome	patients	at	long-	term	
follow-	up
F IGURE  2 Symptom	relief	for	the	global	
symptom	question	at	each	time-	point
n=103
12 (12%)
Sasfactory relief
of symptoms
63 (61%)
Sasfactory relief
of symptoms
44 (70%)
Unsasfactory relief
of symptoms
19 (30%)
Unsasfactory relief
of symptoms
40 (39%)
Sasfactory relief
of symptoms
15 (38%)
Unsasfactory relief
of symptoms
25 (63%)
Baseline Short-term follow-up Long-term follow-up
Paents with sasfactory
relief of symptoms at
long-term follow-up
59 (57%)
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compared	with	the	‘habitual’	group	(10.4±12.7	g/d	vs	16.9±19.4	g/d,	
P=.072).
Patients	in	the	‘adapted	FODMAP’	group	reported	a	significantly	
lower	 overall	 intake	 of	 high-	FODMAP	 food	 groups	 (1195±658	g/d	
vs 1751±1015 g/d, P=.004)	 and	 a	 significantly	 higher	 overall	 intake	
of	 low-	FODMAP	 food	 groups	 (2770±1236	g/d	 vs	 1857±983	g/d,	
P=.003)	than	patients	in	the	‘habitual’	group	(Table	3).	There	were	sim-
ilar	overall	intakes	between	groups	for	high-	and	low-	FODMAP	cereals	
and	grains,	and	the	only	significant	findings	for	sub-	groups	of	cereals	
and	grains	sub-	group	were	that	the	‘adapted	FODMAP’	group	had	a	
higher	 intake	of	 low-	FODMAP	bread	 (difference	27.04	g/d,	P=.022)	
and	 a	 lower	 intake	 of	 high-	FODMAP	 pasta	 (difference	 −26.7	g/d,	
p=0.010)	compared	with	the	‘habitual’	group.	The	‘adapted	FODMAP’	
group	reported	a	higher	intake	of	low-	FODMAP	milk	and	milk	prod-
ucts	 (difference	 415	g/d,	 P=.023),	 specifically	 low-	FODMAP	 milk	
(difference	 393	g/d,	 P=.024),	 and	 low-	FODMAP	 vegetables	 (differ-
ence 220 g/d, P=.020)	and	a	lower	intake	of	fats	and	oils	(difference	
−11.4	g/d,	P=.003)	compared	with	the	‘habitual’	group.
Patients	 in	the	 ‘adapted	FODMAP’	group	consumed	significantly	
less	 onion	 and	 garlic	 than	 patients	 in	 the	 ‘habitual’	 group	 (onion:	
11.4±19.1 g/d vs 22.9±27.2 g/d, P−.032;	 garlic	 0.32±0.63	g/d	 vs	
1.25±1.83	g/d,	P<.001).
Significantly	 fewer	patients	 in	 the	 ‘adapted	FODMAP’	group	ate	
high	fructan	foods	at	least	once	a	week	(21%	vs	30%	P<.001)	or	foods	
containing	high	 levels	of	free	fructose	at	 least	once	a	week	(17%	vs	
27% P<.001)	compared	with	the	‘habitual’	group,	and	there	were	no	
differences between groups for foods containing high levels of lactose, 
galacto-	oligosaccharides,	sorbitol,	or	mannitol	(Table	4).
There	 were	 no	 significant	 differences	 between	 groups	 for	 the	
majority	 of	 components	 of	 dietary	 acceptability	 (Table	5)	 except	 for	
the	following.	Seventy-	two	(86%)	patients	in	the	‘adapted	FODMAP’	
group	reported	their	diet	was	more	expensive	than	prior	to	following	
the	diet,	compared	with	only	8	(42%)	patients	in	the	‘habitual’	group	
(P<.001).	The	‘adapted	FODMAP’	group	reported	increased	difficulty	
eating	out	at	restaurants	compared	with	the	‘habitual’	group	(66	[79%]	
vs	11	 [58%]	P=.013),	eating	at	 family	and	friends’	houses	 (61	 [72%]	
vs	9	[48%]	P=.009),	and	eating	when	traveling	(63	[76%]	vs	9	[48%]	
P=.014).	However,	there	were	no	significant	differences	for	any	of	the	
components	of	food-	related	QOL	between	groups	(Table	5).
3.3 | Healthcare utilization and resources
There	 were	 no	 significant	 differences	 for	 healthcare	 utilization	 be-
tween	the	‘adapted	FODMAP’	and	‘habitual’	groups	for	either	visiting	
a	GP	(33	[39%]	vs	9	[47%]	P=.431)	or	gastroenterologist	(34	[41%]	vs	
8	 [42%]	P=.390).	Additionally,	 there	were	no	 significant	differences	
for	the	numbers	of	days	absent	from	work	between	groups	with	15	
(18%)	‘adapted	FODMAP’	patients	vs	3	(16%)	‘habitual’	diet	patients	
(P=.775)	taking	at	least	3	days	off	work	in	the	last	12	months	due	to	
gastrointestinal symptoms.
Approximately	half	of	patients	reported	taking	no	medication	at	long-	
term	follow-	up,	39	(46%)	of	the	‘adapted	FODMAP’	vs	10	(53%)	of	the	
‘habitual’	group	(P=.625).	Since	low-	FODMAP	advice,	significantly	more	
patients	in	the	‘adapted	FODMAP’	group,	22	(26%)	ceased	medication	
compared	with	only	1	(5%)	patient	in	the	‘habitual’	group	(P=.048).	For	
the	‘adapted	FODMAP’	group,	11	(13%)	patients	started	new	medication	
compared	with	3	(16%)	in	the	‘habitual’	group	(P=.757)	and	3	(4%)	of	the	
‘adapted	FODMAP’	group	reported	a	change	in	medication	over	the	past	
12	months	compared	with	no	patients	in	the	‘habitual’	group	(P=.403).
Patients	 in	 the	 ‘adapted	 FODMAP’	 group	 had	 a	 greater	 depen-
dency on supplementary resources to support their diet than those 
in	 the	 ‘habitual’	 group	 (P<.001),	 with	 just	 under	 half	 of	 ‘adapted	
FODMAP’	patients	 (42%)	using	dietary	 information	provided	by	 the	
dietitian,	 19%	 using	websites	with	 low-	FODMAP	 recipes,	 and	 18%	
using	low-	FODMAP	cookbooks.
4  | DISCUSSION
This	is	the	first	study	to	comprehensively	report	on	the	long-	term	im-
plications	of	 the	 low-	FODMAP	diet	 in	patients	with	 IBS	6-	18	months	
following	dietitian-	led	education.	A	majority	of	patients	(82%)	educated	
on	the	low-	FODMAP	diet	continued	with	a	personalized	adaptation	of	
the	diet	 to	 self-	manage	 their	 symptoms	 in	 the	 long	 term	and	57%	of	
F IGURE  3 Proportion	of	patients	
reporting the presence of individual 
gastrointestinal symptoms at baseline, 
short-	term	follow-	up	and	long-	term	
follow-	up	(n=103)	 	Baseline	 	Short-
term	follow-up	 	Long-term	follow-up	P 
Significant	differences	between	baseline	
and	long-	term	follow-	up
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all	patients	who	received	low-	FODMAP	education	continued	to	report	
long-	term	satisfactory	relief.	Nutritional	requirements	were	met	by	the	
majority	of	patients	and	long-	term	nutritional	adequacy	was	not	com-
promised	when	compared	with	the	‘habitual’	diet	group.	Overall,	patients	
found	the	‘adapted	FODMAP’	diet	acceptable	and	it	did	not	negatively	
affect	their	food-	related	QOL,	healthcare	utilization,	and	work	absentee-
ism	more	than	patients	who	had	returned	to	a	‘habitual’	diet.
Our	 finding	 that	 dietary	 adherence	 to	 the	 low-	FODMAP	 diet	 is	
maintained in the long term and is associated with improved symptom 
response	is	indicative	of	the	therapeutic	value	of	the	diet	for	long-	term	
management.	Short-	term	studies	have	demonstrated	consistent	and	
reproducible findings on overall symptoms10,13,14,16,17 and emerging, 
long-	term	data	are	also	supportive.	After	a	median	of	16	months	fol-
lowing	FODMAP	education,	86%	of	patients	with	IBS	and	inflamma-
tory	 bowel	 disease	 reported	 a	 partial	 (54%)	 or	 full	 (32%)	 symptom	
response to the diet,23	consistent	with	our	findings.	An	earlier	retro-
spective study, which investigated adherence and clinical effective-
ness	of	a	partial	low-	FODMAP	diet	(fructose	and	fructan	restriction)	
found	 that	 at	 14	months	 follow-	up	 77%	 of	 patients	were	 adherent	
to the diet with 76% reporting significant improvement in abdominal 
TABLE  2  Intakes	of	energy,	nutrients,	and	FODMAPs	for	IBS	patients	at	long-	term	follow-	up
Intakes (mean±SD)
Pa
Dietary 
reference valueb
Meeting requirements (DRV),  
n (%)
Pc
Habitual 
diet (n=19)
Adapted FODMAP 
diet (n=84)
Habitual 
diet n (%)
Adapted FODMAP 
diet n (%)
Energy	kcal/d 2219±831 2147±759 .715 2605	(M) 2079	(F) 11	(58) 43	(51) .597
Protein	g/d 91.5±38.0 99.1±38.3 .437 M 55.5 F 45 15	(79) 82	(98) .010
Fat g/d 87.7±45.7 70.1±33.4 .056 35% of food energy 10	(53) 26	(31) .073
Carbohydrate	g/d 250±94.4 252±95.5 .925 50% of food energy 12	(63) 53	(63) .996
Starch	g/d 122±57.3 128±56.9 .696
Total	sugars	g/dd 122±55.2 122±62.9 .990
Dietary fiber g/d 24.9±9.47 26.8±11.5 .500 30 14	(74) 71	(85) .261
Calcium	mg/d 960±608 1168±695 .230 700 12	(63) 64	(76) .243
Iron mg/d 12.9±4.10 13.9±4.70 .411 8.7	(M) 14.8	(F) 12	(63) 57	(68) .694
Zinc mg/d 12.7±5.40 14.4±5.35 .231 M 9.5 F 7.0 15	(79) 79	(94) .058
Magnesium mg/d 342±111 385±134 .198 M 300 F 270 14	(74) 64	(76) .243
Sodium	g/d 2.70±1.40 2.50±1.40 .849 1.6 14	(74) 60	(71) .843
Potassium	g/d 3.77±1.20 4.30±1.50 .191 3.5 11	(58) 54	(64) .602
Phosphorus	mg/d 1757±756 1879±1340 .704 550 19	(100) 83	(99) .816
Vitamin	A	ug/de 1429±845 2147±1482 .045 M 700 F 600 18	(95) 77	(92) .652
Thiamin	mg/d 1.40±0.60 1.87±1.00 .121 M 1.0 F	0.8 18	(95) 83	(99) .245
Riboflavin mg/d 2.37±1.10 2.97±1.60 .093 M 1.3 F 1.1 16	(84) 83	(99) .019
Niacin	mg/d 21.4±7.00 25.37±10.2 .119 M 17 F 13 19	(100) 84	(100) 1.000
Folate ug/d 318±108 398±143 .024 200 17	(90) 83	(99) .087
Vitamin	C	mg/d 168±86.2 220±143 .129 40 19	(100) 84	(100) 1.000
Total	FODMAPS	g/d 29.4±22.9 20.6±14.9 .039
Fructo-	oligosaccharides	
g/d
2.50±1.30 2.00±1.40 .160
Galacto-	oligosaccharides	
g/d
1.00±0.60 1.30±1.50 .326
Lactose	g/d 16.9±19.4 10.4±12.7 .072
Excess	fructose	g/d 6.20±8.10 4.70±10.4 .561
Sorbitol	g/d 2.17±1.90 1.60±1.70 .208
Mannitol g/d 0.60±0.60 0.50±0.40 .267
DRV dietary reference value;
aIndependent t	test	between	‘habitual’	diet	vs	‘adapted	FODMAP’	diet.
bWhere	applicable	male	(M)	19-	50	years	and	female	(F)	19-	50	years	values	are	given	as	an	example	but	the	value	may	not	apply	if	>50	years.30
cChi-	squared	between	numbers	meting	the	requirement	(DRV)	for	‘habitual’	diet	vs	‘adapted	FODMAP’	diet.
dincluded sucrose, lactose, glucose, and fructose—DRV only available for free sugars so not assessed.
eTotal	vitamin	A	equivalents.
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symptoms.12	Prospective	data	on	adherence	are	similar	to	our	current	
study;	76%	of	participants	were	adherent	to	the	low-	FODMAP	diet	at	
a	mean	16	months	follow-	up,	but	satisfaction	with	symptom	response	
was slightly greater at 72% of patients than that observed herein.18 
In	a	randomized	non-	blinded	trial	which	compared	the	low-	FODMAP	
diet	with	hypnotherapy,	82%	of	patients	who	had	responded	to	the	
diet	maintained	satisfactory	relief	of	symptoms	at	6	months,	equating	
to	58%	of	all	patients	who	had	received	dietary	advice.24	Cumulatively,	
long-	term	adherence	to	the	low-	FODMAP	diet	is	not	only	maintained	
in the majority of patients but is also associated with significant 
TABLE  3 Dietary	intake	of	high-	and	low-	FODMAP	food	groups	for	IBS	patients	at	long-	term	follow-	up
Food group
Habitual diet (n=19) Adapted FODMAP diet (n=84)
PMean±SD (g/d) Mean±SD (g/d)
Cereals	and	grains	high	FODMAP 258±174 194±146 .098
Cereals	and	grains	low	FODMAPa 249±239 326±247 .22
Grain	high	FODMAP 21.8±27.1 15.79±32.4 .452
Grain	low	FODMAP 164±213 173±177 .859
Bread	high	FODMAP 76.6±75.0 61.4±71.5 .409
Bread	low	FODMAPa 1.56±5.31 28.6±50.5 .022
Breakfast	cereal	high	FODMAP 47.4±46.8 43.4±60.4 .787
Breakfast	cereal	low	FODMAP 23.2±34.8 28.6±41.5 .599
Pasta	high	FODMAP 47.5±55.7 20.8±35.4 .010
Pasta	low	FODMAPa 39.8±55.4 63.7±77.3 .204
Cereal	products	high	FODMAP 29.5±27.4 22.7±30.9 .380
Cereal	products	low	FODMAPa 20.4±25.7 32.5±49.7 .306
Milk	&	milk	products	high	FODMAP 688±820 416±529 .074
Milk	&	milk	products	low	FODMAPb 148±234 563±777 .023
Milk	high	FODMAP 552±830 295±486 .076
Milk	low	FODMAPb 82.7±157 476±742 .024
Cheese	high	FODMAP 7.31±18.3 11.8±36.0 .600
Cheese	low	FODMAP 27.5±38.2 29.3±50.2 .883
Yoghurt	high	FODMAP 97.5±141 94.5±137 .933
Yoghurt	low	FODMAPb 25.5±91.8 46.2±103 .422
Other	dairy	high	FODMAP	eg,	Ice	cream 17.1±34.8 10.1±18.2 .211
Other	dairy	low	FODMAP 7.38±11.6 5.91±10.1 .579
Fruit	high	FODMAP 233±176 188±226 .412
Fruit	low	FODMAP 289±227 460±387 .067
Vegetables	high	FODMAP 196±122 165±170 .453
Vegetables	low	FODMAP 488±250 708±387 .020
Proteins 184±126 199±111 .601
Fats 26.6±23.5 15.2±12.5 .003
Drinks	high	FODMAP 219±472 146±350 .441
Drinks	low	FODMAP 394±697 432±536 .791
Sugars	high	FODMAPc 11.7±17.6 4.15±6.55 .002
Sugars	low	FODMAP 15.4±16.8 20.5±21.8 .344
Miscellaneous	and	processed	high	FODMAP 194±152 117±110 .012
Miscellaneous	and	processed	low	FODMAP 70.2±104 53.8±41.6 .266
TOTAL	high	FODMAP 1751±1015 1195±658 .004
TOTAL	low	FODMAP 1857±983 2770±1236 .003
Independent t test.
aFoods	described	as	gluten-	free	in	the	food	frequency	questionnaire	were	included	in	this	group	or	sub-	group.
bFoods	described	as	lactose-	free	in	the	food	frequency	questionnaire	were	included	in	this	group	or	sub-	group.
cIncludes	honey,	sugar-	free	chewing	gum	(high	in	polyols).
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improvement	in	symptom	response.	The	variation	observed	between	
studies	may	be	explained,	at	least	in	part,	by	differences	in	study	de-
sign such as the high level of response bias in retrospective studies.
Individual	 symptom	 severity	 reduced	 at	 both	 short-	 and	 long-	
term	 follow-	up.	 Significant	 reductions	 in	 abdominal	 pain,	 bloating,	
flatulence, incomplete evacuation, and lethargy were reported, with 
pain,	bloating,	and	flatulence	decreasing	by	more	than	one-	third	in	the	
long	term.	These	findings	are	consistent	with	existing	short10,13,14,16,17 
and	long-	term	literature18,23,24,38 as well as a recent systemic review 
and	meta-	analysis.39	The	study	cohort	had	a	low	reporting	of	abnor-
mal	 stool	 frequency	at	baseline	which	 is	 not	uncommon	 in	 IBS	due	
to	 its	relapsing	and	remitting	nature.	The	enduring	symptom	allevia-
tion	associated	with	the	diet	is	a	remarkable	advantage	of	FODMAP	
therapy particularly compared to pharmaceutical management where 
TABLE  4 The	percentage	of	IBS	patients	consuming	high-	
FODMAP	foods	at	least	once	a	week	at	long-	term	follow-	up
Consumed at least once a 
week (% of patients)
PHabitual diet
Adapted 
FODMAP diet
Fructans 30.2 21.1 <.001
Galacto-	oligosaccharides 28.8 24.5 .11
Lactose 22.6 19 .183
Free fructose 26.8 17 <.001
Sorbitol 30.4 27 .201
Mannitol 37.5 39.9 .588
TABLE  5 Dietary	acceptability	and	food-	related	quality	of	life	of	IBS	patients	at	long-	term	follow-	up
Habitual diet n (%) Adapted FODMAP diet n (%)
PAgree Neutral Disagree Agree Neutral Disagree
Dietary acceptability
I find it easy to buy suitable foods for my current diet at my 
normal	supermarkets	or	shops
14	(74) 1	(5) 4	(21) 57	(68) 9	(11) 18	(21) .759
I am able to buy foods suitable for my current diet at my normal 
supermarkets	or	shopsa
16	(85) 1	(5) 2	(10) 63	(76) 9	(11) 11	(13) .698
I	use	high	street/online	speciality	shops	(eg,	health	food	shops)	
to buy food for my current diet
7	(41) 6	(35) 4	(24) 28	(33) 14	(17) 42	(50) .086
It	takes	extra	time	to	shop	for	my	current	diet 8	(43) 5	(26) 6	(32) 54	(64) 11	(13) 19	(23) .172
It	takes	extra	time	to	cook	for	my	current	diet 8	(42) 3	(16) 8	(43) 38	(45) 11	(13) 35	(42) .943
I	find	food	labeling	is	adequate	to	allow	me	to	confidently	
choose suitable foods
10	(53) 8	(42) 1	(5) 53	(63) 16	(19) 15	(17) .067
The	cost	of	my	current	diet	is	more	expensive 8	(42) 9	(47) 2	(11) 72	(86) 11	(13) 1	(1) <.001
Does	eating	out	at	restaurants	make	it	more	difficult	for	you	to	
follow your current diet?
11	(58) 1	(5) 7	(37) 66	(79) 8	(10) 10	(12) .030
Does	eating	out	at	friends/families	make	it	more	difficult	for	you	
to follow your current diet?
9	(48) 3	(16) 7	(37) 61	(72) 15	(18) 8	(9) .009
Does	travel	(overseas/UK)	make	it	more	difficult	for	you	to	
follow your current diet?a
9	(48) 3	(16) 7	(37) 63	(76) 11	(13) 9	(11) .014
Overall, I find my current diet tasty and enjoyable 14	(74) 3	(16) 2	(10) 53	(63) 15	(18) 16	(19) .622
I can incorporate my current diet easily into my lifea 10	(55) 4	(22) 4	(22) 47	(56) 20	(24) 17	(20) .978
My current dietary needs have created stress with my family/
friendsa
5	(28) 3	(17) 10	(55) 20	(24) 16	(19) 48	(57) .929
Food-	related	quality	of	life
Food and meals are positive elements of my life 14	(74) 3	(16) 2	(11) 57	(68) 14	(17) 13	(15) .842
I am generally pleased with my food 10	(53) 7	(37) 2	(11) 47	(56) 23	(27) 14	(16) .643
My life in relation to food and meals is close to my ideala 9	(45) 5	(25) 6	(30) 25	(29) 27	(32) 32	(38) .329
With	regard	to	food,	the	conditions	of	my	life	are	excellent 8	(42) 7	(37) 4	(21) 27	(33) 28	(34) 28	(34) .535
Food and meals give me satisfaction in daily life 10	(53) 7	(37) 2	(10) 47	(56) 20	(24) 17	(20) .401
I wish my meals were much more pleasant part of my lifea 6	(34) 6	(33) 6	(34) 35	(42) 20	(24) 29	(35) .674
When	I	think	of	my	next	meal,	I	only	see	problems,	obstacles	and	
disappointmentsa
4	(23) 5	(28) 9	(50) 15	(18) 17	(20) 52	(62) .189
aMissing n=1.
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symptom relief is limited at best.40	Dietary	management	of	IBS	is	asso-
ciated	with	increased	feelings	of	self-	control	and	empowerment41 and 
may	foster	greater	long-	term	self-	management.
The	lack	of	robust	 long-	term	nutrient	data	and	the	identification	
of	at	risk	nutrients	 in	short-	term	studies14	have	raised	questions	re-
garding	the	nutritional	adequacy,	and	therefore	suitability,	of	the	diet	
for	 long-	term	management.	A	key	 finding	herein	 is	 that	an	 ‘adapted	
FODMAP’	diet	maintained	for	6-	18	months	achieved	nutritional	ad-
equacy	and	any	deficits	 in	energy	or	nutrient	intakes	were	similar	to	
those	expected	in	the	background	population.42
In	short-	term	studies	of	the	low-	FODMAP	diet,	total	carbohydrate	
intakes	 of	 200	g/d	 have	 been	 observed	 following	 FODMAP	 restric-
tion;9,13 however, the current study reports a 20% higher total carbo-
hydrate	intake.	A	gluten-	free	diet	for	management	of	celiac	disease	is	
associated with a similar trend that is a reduction in carbohydrate in-
take	observed	in	patients	new	to	the	diet	followed	by	an	increase	in	ex-
perienced users.43,44	There	was	no	reduction	in	long-	term	dietary	fiber	
intake.	Data	on	dietary	fiber	intakes	in	short-	term	studies	are	inconsis-
tent.	Two	studies	 report	 similar	 levels	 to	baseline,13,45 while another 
shows	 a	 significant	 reduction	 in	 intake	 following	 FODMAP	 restric-
tion.9	A	 reduction	 in	dietary	 fiber	 intake	during	FODMAP	restriction	
is plausible given the stringent reduction of some staple cereals and 
legumes. However, in the long term, we observed a greater propor-
tion	of	patients	meeting	the	dietary	fiber	nutrient	requirements	on	an	
‘adapted	FODMAP’	diet	having	reintroduced	foods	high	in	FODMAPs	
to individual tolerance than for those patients who had returned to a 
‘habitual’	diet.	This	may	be	due	to	 increased	familiarity	with	the	diet	
and	greater	understanding	of	low-	FODMAP,	high-	fiber	food	choices.
Previous	 research	 suggests	 that	 FODMAP	 restriction	 leads	 to	
lower	calcium	intakes	in	the	short	term.13 In the current study, mean 
calcium	 intakes	were	 adequate	 and	 there	was	 no	 difference	 in	 the	
proportion	 of	 patients	 that	 achieved	 their	 calcium	 requirement	 on	
an	‘adapted	FODMAP’	diet	compared	with	a	‘habitual’	diet.	This	may	
be	due	to	a	significant	increase	in	lactose-	free	milk	consumption	(in-
cluding	calcium-	fortified	plant-	based	milks)	in	the	‘adapted	FODMAP’	
group such that calcium levels were maintained.
This	 is	 the	 first	 study	 to	 evaluate	 the	 intake	 of	 foods	 and	 food	
groups	in	patients	following	a	low-	FODMAP	diet.	Patients	who	contin-
ued	to	follow	an	‘adapted	FODMAP’	diet	had	a	lower	intake	of	garlic,	
onion,	ready-	meals,	some	high	fructan	cereal-	based	foods	(eg,	pasta),	
high-	FODMAP	sugars	(eg,	honey),	and	high-	FODMAP	miscellaneous	
and	processed	foods	compared	with	the	 ‘habitual’	diet.	Cereal	prod-
ucts	including	pasta,	wheat	bran,	and	breakfast	cereals	have	previously	
been identified as symptomatic triggers and the reduction of these is 
unsurprising.46	A	reduced	intake	of	high-	fat	foods	and	miscellaneous	
and	processed	high-	FODMAP	foods	for	the	‘adapted	FODMAP’	group	
signifies	a	move	toward	less	high-	fat,	energy-	dense	food	options	and	
may,	 in	part,	explain	the	reported	weight	 loss	observed	in	over	40%	
of	those	on	an	‘adapted	FODMAP’	diet.	Previously,	patients	with	IBS	
report greater induction of symptoms with fatty foods compared to 
controls47	and	those	with	IBS	show	hypersensitivity	to	lipid	infusions	
compared to healthy individuals.48 Interestingly, different proportions 
of	fat,	protein,	and	carbohydrate	may	aggravate	IBS,	particularly	IBS-	C,	
via hormonal mediators of gut endocrine cells which are understood 
to regulate gastrointestinal functions including visceral sensation, mo-
tility, and secretion.49 In clinical practice, dietary manipulation of car-
bohydrate	or	fat	or	an	increase	in	protein	intake	are	associated	with	
symptom improvements in some patients.49
An	 increase	 of	 low-	FODMAP	 fruit	 and	vegetables	 as	 seen	 here	
is	equivalent	 to	 two	portions	of	 fruit	and	vegetables	daily,	 again	 in-
dicative	of	more	healthful	dietary	patterns	in	the	‘adapted	FODMAP’	
group.	Recent	guidelines	 for	 IBS	report	 that	 in	a	heterogeneous	 IBS	
population,	 lower	 intakes	of	 fruit	 and	vegetables	and	higher	 intakes	
of fast foods have been reported to be involved in symptom genera-
tion although the evidence is insufficient to indicate that dietary habits 
have a role to play.22	Thus,	 if	 a	 low-	FODMAP	diet	 can	 improve	 di-
etary	habits	and	decrease	overall	intake	of	foods	high	in	fat	in	the	long	
term; it may have additional benefits to health and warrants further 
research.
Further	 investigation	 to	 determine	 which	 individual	 FODMAPs	
and	high-	FODMAP	foods	can	be	successfully	reintroduced	is	of	great	
interest	and	may	help	to	determine	whether	any	specific	FODMAPs	or	
foods	are	more	likely	to	be	tolerated,	and	which	FODMAPs	might	be	
associated with provocation of specific symptoms.
A	reduction	in	bodyweight	has	been	observed	in	individuals	ran-
domized	 to	 a	 low-	FODMAP	 compared	 with	 ‘habitual’	 diet13 and a 
reduction	 in	 energy	 intake	 in	 another	 study.9	Despite	energy	 intake	
not being measured at baseline in the current study, 42% of patients 
reported	weight	 reduction	 at	 long-	term	 follow-	up,	 this	may	 be	 due	
to	 adopting	 a	 healthier	 eating	 pattern	 as	 described	 above.	Weight	
and	 weight	 loss	 was	 self-	reported	 and	 should	 be	 interpreted	 with	
caution.50
To	 the	 best	 of	 our	 knowledge,	 this	 is	 the	 first	 study	 to	 investi-
gate	 the	 long-	term	 acceptability	 of	 the	 low-	FODMAP	 diet.	We	 re-
port the diet causes disruption for eating out and with family/friends. 
Consistent	with	a	recent	retrospective	study,	the	diet	was	associated	
with increased cost.23	All	of	these	issues	can	be	addressed	during	di-
etetic consultation.14,15	The	 low-	FODMAP	 diet	 does	 not	 negatively	
affect	 food-	related	 QOL	 nor	 does	 it	 adversely	 affect	 enjoyment	 of	
meals,	cooking,	shopping	and	integration	into	current	lifestyles	com-
pared	with	patients	who	consume	their	‘habitual’	diet.	Given	the	large	
proportion	 of	 individuals	 affected	 by	 IBS	 and	 the	 known	 reduction	
in	their	QOL4 alongside dissatisfaction with current treatments by at 
least 60% of patients,51	these	findings	are	of	importance.	They	demon-
strate that the diet is not only an effective treatment but it is also 
acceptable	with	improved	QOL	for	this	chronic	disorder	and	patients	
with inflammatory bowel disease.17,23,52
The	economic	impact	of	IBS	is	notable.1,53,54 Recent data suggest 
that	 IBS	 accounts	 for	 in	 excess	 of	 £80	million	 in	 prescription	 costs	
alone	and	IBS	patients	are	significant	users	of	healthcare	accounting	
for 7.5% of total outpatient visits across specialities.7	The	current	find-
ings indicate that healthcare usage and medication use is similar among 
those	on	an	‘adapted	FODMAP’	diet	and	a	‘habitual’	diet;	however,	the	
expenditure	 appears	 to	 be	 slightly	 lower	 than	 that	 reported	 for	UK	
patients	with	IBS.1	Further	work	is	required	to	assess	healthcare	usage	
of	patients	who	do	and	do	not	receive	low-	FODMAP	education.
     |  11 of 13O’KEEFFE Et al.
There	are	several	limitations	of	this	study.	Firstly,	only	27%	of	the	
original	sample	invited	to	take	part	completed	the	study	which	is	lower	
than	other	similar	postal	questionnaire	studies.18,55While	we	acknowl-
edge that it is possible we may have sampled a biased population of pa-
tients	who	had	responded	to	the	low-	FODMAP	diet,	global	symptom	
data	from	the	baseline	and	short-	term	follow-	up	were	similar	for	those	
who did and did not reply to the initial invite as reported previously.18 
Over	80%	of	subjects	were	recruited	from	an	urban	setting	although	
most did not reply or had moved. Half of subjects invited from a rural 
area	 were	 recruited	 to	 the	 study.	 The	 higher	 response	 rate	 among	
these participants may possibly reflect the less transient nature of rural 
communities. In addition, the rural population was significantly older 
and included a smaller proportion of males than the urban population 
perhaps	due	to	greater	work	opportunities	for	the	younger	population	
and for males in the urban area compared to elsewhere as reported 
from national data.56	 Secondly,	 the	 study	 design	was	 a	 prospective	
questionnaire-	based	study	that	was	uncontrolled	and	unblinded,	thus	
increasing	the	risk	of	bias.	Finally,	given	the	lack	of	a	disease	activity	
biomarker	in	IBS,	symptom	evaluation	was	subjective	and	we	acknowl-
edge the limitations associated with subjective measures.22,57 Dietary 
intake	was	assessed	by	a	food	frequency	questionnaire	which	has	been	
validated	to	assess	FODMAP	intake;	however,	not	in	a	UK	population.	
As	with	all	food	frequency	questionnaires	this	approach	can	underesti-
mate	or	overestimate	intake	of	certain	foods.58
In	summary,	we	report	that	the	low-	FODMAP	diet	is	an	effective	
long-	term	 strategy	 for	 the	 management	 of	 IBS	 addressing	 an	 area	
which	has,	to	date,	been	largely	unexplored.59–61
5  | CONCLUSION
This	study	prospectively	evaluated	the	long-	term	impact	of	the	low-	
FODMAP	diet	on	symptom	response,	dietary	 intake,	patient	accept-
ability,	and	healthcare	utilization	in	a	large	cohort	of	patients	with	IBS.	
Patients	report	that	the	diet	is	clinically	effective	with	57%	reporting	
long-	term	satisfactory	symptom	relief.	Individuals	who	have	received	
comprehensive	education	on	the	low-	FODMAP	diet	have	completed	
short-	term	FODMAP	restriction	followed	by	FODMAP	reintroduction	
to	individual	tolerance.	A	low-	FODMAP	diet	can	be	nutritionally	ade-
quate	up	to	18	months	after	initial	education	and	patients	find	that	the	
diet	is	acceptable	and	does	not	adversely	impact	on	food-	related	QOL.
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